These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30230539)

  • 1. Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk.
    Purdue MP; Lan Q; Hoffman-Bolton J; Hildesheim A; Callahan CL; Strickland P; Visvanathan K; Rothman N
    Int J Cancer; 2019 Apr; 144(8):1780-1785. PubMed ID: 30230539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.
    Purdue MP; Lan Q; Langseth H; Grimsrud TK; Hildesheim A; Rothman N
    Int J Cancer; 2020 Jun; 146(12):3312-3319. PubMed ID: 31523805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble levels of CD27 and CD30 are associated with risk of non-Hodgkin lymphoma in three Chinese prospective cohorts.
    Bassig BA; Shu XO; Koh WP; Gao YT; Purdue MP; Butler LM; Adams-Haduch J; Xiang YB; Kemp TJ; Wang R; Pinto LA; Zheng T; Ji BT; Hosgood HD; Hu W; Yang G; Zhang H; Chow WH; Kim C; Seow WJ; Zheng W; Yuan JM; Lan Q; Rothman N
    Int J Cancer; 2015 Dec; 137(11):2688-95. PubMed ID: 26095604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
    Purdue MP; Lan Q; Martinez-Maza O; Oken MM; Hocking W; Huang WY; Baris D; Conde B; Rothman N
    Blood; 2009 Sep; 114(13):2730-2. PubMed ID: 19638620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.
    Rhee J; Birmann BM; De Roos AJ; Epstein MM; Martinez-Maza O; Breen EC; Magpantay LI; Levin LI; Visvanathan K; Hosgood HD; Rohan TE; Smoller SW; Bassig BA; Qi L; Shu XO; Koh WP; Zheng W; Yuan JM; Weinstein SJ; Albanes D; Lan Q; Rothman N; Purdue MP
    Int J Cancer; 2023 Mar; 152(5):865-878. PubMed ID: 36151863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma.
    Widney D; Gundapp G; Said JW; van der Meijden M; Bonavida B; Demidem A; Trevisan C; Taylor J; Detels R; Martínez-Maza O
    Clin Immunol; 1999 Nov; 93(2):114-23. PubMed ID: 10527687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.
    Purdue MP; Lan Q; Bagni R; Hocking WG; Baris D; Reding DJ; Rothman N
    Cancer Res; 2011 Jul; 71(14):4898-907. PubMed ID: 21632552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occupational exposure to trichloroethylene is associated with a decline in lymphocyte subsets and soluble CD27 and CD30 markers.
    Lan Q; Zhang L; Tang X; Shen M; Smith MT; Qiu C; Ge Y; Ji Z; Xiong J; He J; Reiss B; Hao Z; Liu S; Xie Y; Guo W; Purdue MP; Galvan N; Xin KX; Hu W; Beane Freeman LE; Blair AE; Li L; Rothman N; Vermeulen R; Huang H
    Carcinogenesis; 2010 Sep; 31(9):1592-6. PubMed ID: 20530238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.
    Kok M; Bonfrer JM; Korse CM; de Jong D; Kersten MJ
    Tumour Biol; 2003; 24(1):53-60. PubMed ID: 12743427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of Immune Activation and Inflammation, and Non-Hodgkin Lymphoma: A Meta-Analysis of Prospective Studies.
    Makgoeng SB; Bolanos RS; Jeon CY; Weiss RE; Arah OA; Breen EC; Martínez-Maza O; Hussain SK
    JNCI Cancer Spectr; 2018 Dec; 2(4):pky082. PubMed ID: 30873511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses.
    Hosnijeh FS; Portengen L; Späth F; Bergdahl IA; Melin B; Mattiello A; Masala G; Sacerdote C; Naccarati A; Krogh V; Tumino R; Chadeau-Hyam M; Vineis P; Vermeulen R
    Int J Cancer; 2016 May; 138(10):2357-67. PubMed ID: 26684261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.
    Levin LI; Breen EC; Birmann BM; Batista JL; Magpantay LI; Li Y; Ambinder RF; Mueller NE; Martínez-Maza O
    Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1114-1123. PubMed ID: 28341757
    [No Abstract]   [Full Text] [Related]  

  • 13. Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma.
    Purdue MP; Lan Q; Kemp TJ; Hildesheim A; Weinstein SJ; Hofmann JN; Virtamo J; Albanes D; Pinto LA; Rothman N
    Leukemia; 2015 Jun; 29(6):1429-31. PubMed ID: 25567136
    [No Abstract]   [Full Text] [Related]  

  • 14. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies.
    Kersten MJ; Evers LM; Dellemijn PL; van den Berg H; Portegies P; Hintzen RQ; van Lier RA; von dem Borne AE; van Oers RH
    Blood; 1996 Mar; 87(5):1985-9. PubMed ID: 8634448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of serum and cerebrospinal fluid soluble CD27 in the diagnosis of leptomeningeal involvement of hematolymphoid malignancies.
    Kara IO; Sahin B; Gunesacar R
    Adv Ther; 2007; 24(4):741-7. PubMed ID: 17901023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.
    De Roos AJ; Mirick DK; Edlefsen KL; LaCroix AZ; Kopecky KJ; Madeleine MM; Magpantay L; Martínez-Maza O
    Cancer Res; 2012 Sep; 72(18):4733-43. PubMed ID: 22846913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.
    Edlefsen KL; Martínez-Maza O; Madeleine MM; Magpantay L; Mirick DK; Kopecky KJ; LaCroix AZ; De Roos AJ
    Int J Cancer; 2014 Aug; 135(4):913-22. PubMed ID: 24488825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women.
    Hussain SK; Hessol NA; Levine AM; Breen EC; Anastos K; Cohen M; D'Souza G; Gustafson DR; Silver S; Martínez-Maza O
    Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2084-93. PubMed ID: 24045923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.
    Breen EC; Hussain SK; Magpantay L; Jacobson LP; Detels R; Rabkin CS; Kaslow RA; Variakojis D; Bream JH; Rinaldo CR; Ambinder RF; Martinez-Maza O
    Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1303-14. PubMed ID: 21527584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble cytokine receptor CD30 in atopic disorders: a case-control study.
    Latza U; Davis S; Wilhelm D; McKnight B; Seyfarth M; Stein H
    Clin Exp Allergy; 1999 Jan; 29(1):97-104. PubMed ID: 10051708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.